Have a feature idea you'd love to see implemented? Let us know!

CASI CASI Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CASI

Price (delayed)

$2.65

Market cap

$40.53M

P/E Ratio

N/A

Dividend/share

N/A

EPS

N/A

Enterprise value

$43.12M

CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is ...

Highlights
The equity has soared by 53% since the previous quarter but it has dropped by 52% year-on-year
CASI Pharmaceuticals's quick ratio has decreased by 46% YoY
The debt has increased by 3.6% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.casipharmaceuticals.com/
Peers: RGEN CRIS NBIX AMGN

Key stats

What are the main financial stats of CASI
Market
Shares outstanding
15.29M
Market cap
$40.53M
Enterprise value
$43.12M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.59
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
N/A
Gross profit
N/A
Net income
N/A
EBIT
N/A
EBITDA
N/A
Free cash flow
N/A
Per share
EPS
N/A
EPS diluted
N/A
Free cash flow per share
N/A
Book value per share
$1.02
Revenue per share
N/A
TBVPS
$4.09
Balance sheet
Total assets
$63.62M
Total liabilities
$49.77M
Debt
$19.12M
Equity
$13.85M
Working capital
$32.41M
Liquidity
Debt to equity
1.38
Current ratio
3.2
Quick ratio
2.17
Net debt/EBITDA
N/A
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
N/A
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
N/A
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CASI stock price

How has the CASI Pharmaceuticals stock price performed over time
Intraday
-1.49%
1 week
-14.79%
1 month
-49.62%
1 year
-59.17%
YTD
-62.99%
QTD
-56.98%

Financial performance

How have CASI Pharmaceuticals's revenue and profit performed over time
Revenue
N/A
Gross profit
N/A
Operating income
N/A
Net income
N/A
Gross margin
N/A
Net margin
N/A

Growth

What is CASI Pharmaceuticals's growth rate over time

Valuation

What is CASI Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.59
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The equity has soared by 53% since the previous quarter but it has dropped by 52% year-on-year
The stock's P/B is 46% below its last 4 quarters average of 4.8 and 4.1% below its 5-year quarterly average of 2.7

Efficiency

How efficient is CASI Pharmaceuticals business performance

Dividends

What is CASI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CASI.

Financial health

How did CASI Pharmaceuticals financials performed over time
The total assets is 28% greater than the total liabilities
CASI's total liabilities has soared by 109% YoY and by 18% from the previous quarter
CASI Pharmaceuticals's quick ratio has decreased by 46% YoY
The debt is 38% greater than the equity
The equity has soared by 53% since the previous quarter but it has dropped by 52% year-on-year
CASI's debt to equity is down by 33% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.